新的標題：肺癌病理報告分期及術後化療建議-胸腔內科

肺癌病理報告分期？

Lymph node regional (group 11) lymphadenectomy carcinoma metastatic (involved number: 2 total number: 12)Lung left status post neoadjuvant therapy pneumonectomy (1) scar compatible with treatment effect; (2) harmatomaLymph node mediastinum group 5/6 lymphadenectomy no evidence of metastasis (total number: 4)Lymph node mediastinum group 7 lymphadenectomy no evidence of metastasis (total number: 2)Gross DescriptionSpecimen ”Left lung”1. Specimen: lung2. Specimen size : 21 x 12 x 2.2 cm3. Tumor Site: Peribronchial (large) and peripheral (small)4. Tumor Size:* Multiple (Number: 2 )- large: 5 x 3.5 x 2.5 cm- small: 0.6 x 0.5 x 0.5 cm5. Tumor gross configuration:* large: ill-define tan elastic-soft* small: well-defined white firm6. Pleural retraction: not identified7. Obstructive pneumonia: not identifiedSpecimen ”LN5/6”: one fragment 1.3 x 1 x 0.5 cmSpecimen ”LN7”: two fragments up to 0.8 x 0.6 x 0.3 cmRepresentative sections are taken and labeled as:A1-4 P: large tumor A5: small tumorB: non-tumor lung C: bronchovascular marginD: LN5/6 E: LN7F1-2: regional lymph nodeMicroscopic1. Diagnosis:* squamous cell carcinoma (in lymph nodes)* large tumor: fibrosis and foamy cell aggregates compatible with treatment effect* small tumor: hamartoma2. Tumor size:* Not seen in the lung parenchyma3. Histological Grade (IASLC Histopathologic Grading)* G3: Poorly differentiated (any tumor with ＞= 20% high-grade pattern (i.e. solid micropapillary cribriform or complex glandular pattern)4. Section Margin* pulmonary parenchymal margin: uninvolved5. Lymphovascular Invasion:* Not Present6. Visceral Pleural Invasion* The tumor does not invade the visceral pleura (PL0).7. Spread Through Air Spaces: Not identified8. Pathologic Staging (pTNM)(AJCC 8th edition)(1). Primary Tumor (T)ypT0: No evidence of primary tumor(2). Lymph Nodes (N)ypN1: Metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary nodes including involvement by direct extensionNodal StatusN1 (Number involved / Number examined)group 11 (Interlobar): 2 / 12N2 (Number involved / Number examined)Left group 5/6: 0 / 2Left group 7: 0 / 4Extranodal extension: -9. Treatment Effect: Less than or equal to 10% residual viable tumor10. Comment:* The tumor cells are positive for p40 and negative for TTF1 EBER and p16. A squamous cell carcinoma is considered.* The viable tumor cells are only found in the lymph nodes.* The small tumor shows a hematoma.醫師您好我看了我父親左肺全切後的病理報告，因為手術前有做過新輔助治療（化療+免疫）所以手術後分期寫T0N1 胸外科醫師說可以追蹤就好但是我聽說只要淋巴轉移就得做術後的預防性化療，想詢問醫師若是因為新輔助治療後主腫瘤驗不到癌細胞但有顆淋巴轉移那這樣還需要做術後的化療嗎？
那目前肺鱗癌的術後化療的療程通常都是什麼？